Robert E. Claypoole Sells 28,786 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the transaction, the chief executive officer now owns 64,964 shares of the company’s stock, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bioventus Price Performance

Shares of BVS stock opened at $9.71 on Thursday. The stock’s fifty day moving average is $11.02 and its 200-day moving average is $10.19. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a market capitalization of $788.02 million, a PE ratio of -15.92 and a beta of 0.85. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38.

Bioventus (NYSE:BVS) last announced its earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The company had revenue of $138.96 million for the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same quarter in the prior year, the business earned $0.05 earnings per share. Equities research analysts expect that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on BVS shares. Craig Hallum increased their price objective on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, September 27th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group increased their target price on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Hedge Funds Weigh In On Bioventus

Several hedge funds have recently added to or reduced their stakes in BVS. Bank of New York Mellon Corp bought a new position in Bioventus in the second quarter valued at about $647,000. Rhumbline Advisers boosted its holdings in Bioventus by 5,367.9% in the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock valued at $302,000 after acquiring an additional 51,478 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Bioventus by 403.1% in the second quarter. Acadian Asset Management LLC now owns 27,956 shares of the company’s stock valued at $159,000 after acquiring an additional 22,399 shares during the last quarter. American Century Companies Inc. boosted its holdings in Bioventus by 289.5% in the second quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock valued at $973,000 after acquiring an additional 125,736 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Bioventus by 100.7% in the second quarter. Dimensional Fund Advisors LP now owns 117,496 shares of the company’s stock valued at $676,000 after acquiring an additional 58,954 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.